SGLT2 inhibitor gets cardioprotective approval

The TGA has approved an expanded indication for the blood glucose-lowering drug, empagliflozin (Jardiance, Boehringher Ingelheim, Eli Lilly) to protect against risk of cardiovascular death in patients with type 2 diabetes who also have established cardiovascular disease. The cardioprotective indication – a first for any oral anti diabetic therapy – comes off the back of ...

Already a member?

Login to keep reading.

© 2021 the limbic